Edition:
India

Dr.Reddy's Laboratories Ltd (REDY.BO)

REDY.BO on Bombay Stock Exchange

2,032.80INR
3:14pm IST
Change (% chg)

Rs47.95 (+2.42%)
Prev Close
Rs1,984.85
Open
Rs2,000.00
Day's High
Rs2,052.00
Day's Low
Rs1,990.00
Volume
50,800
Avg. Vol
48,723
52-wk High
Rs3,394.95
52-wk Low
Rs1,901.65

REDY.BO

Chart for REDY.BO

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.15
Market Cap(Mil.): Rs329,013.59
Shares Outstanding(Mil.): 165.82
Dividend: 20.00
Yield (%): 1.01

Financials

  REDY.BO Industry Sector
P/E (TTM): 27.38 30.66 31.86
EPS (TTM): 72.46 -- --
ROI: -- 14.54 14.08
ROE: -- 15.62 15.39

BRIEF-Dr.Reddy's Labs unit out-licenses psoriasis drug to Encore Dermatology​

* Says co ‍announces out-licensing of DFD-06 to Encore Dermatology​

22 Aug 2017

BRIEF-Dr.Reddy's Labs says ‍GMP compliance certificate relating to Hyderabad unit not renewed

* ‍GMP compliance certificate relating to co's manufacturing unit in Hyderabad not renewed consequent to recent inspection of plant​

10 Aug 2017

Indian shares decline; Dr. Reddy's, ICICI Bank fall on weak Q1

July 28 India's NSE index took a breather on Friday after hitting record highs in each of the previous four sessions, as disappointing quarterly earnings weighed on bank and pharmaceutical shares.

28 Jul 2017

BRIEF-India's Dr Reddy's expects U.S. "adverse pricing environment" to persist

* COO Abhijit Mukherjee says expects adverse pricing environment in U.S. to persist

27 Jul 2017

BRIEF-Dr.Reddy's Laboratories, CHD Bioscience announce global license & commercialization deal

* Co, CHD Bioscience announce global license & commercialization deal for phase III clinical trial candidate for mitigation of surgical site infections

27 Jul 2017

Dr Reddy's Q1 profit slumps on pricing pressures in U.S.

Dr. Reddy's Laboratories Ltd said its first-quarter profit more than halved from a year ago, as regulatory hurdles and pricing pressures in its biggest market, the United States, dragged on the drugmaker's earnings.

27 Jul 2017

UPDATE 1-India's Dr Reddy's Q1 profit slumps on pricing pressures in U.S.

* North America generics business revenue down 4 percent (Adds details, CEO comment, background)

27 Jul 2017

BRIEF-Dr.Reddy's Laboratories June-qtr consol profit falls about 57 pct

* June quarter consol net profit after tax and share of profit of associates 666 million rupees versus profit of 1.54 billion rupees last year

27 Jul 2017

India's Dr Reddy's Q1 profit slumps 57 pct y/y

July 27 Dr.Reddy's Laboratories Ltd reported a 57 percent slump in its first-quarter profit as regulatory hurdles and pricing pressures in its biggest market, the United States, dragged on the drugmaker's earnings.

27 Jul 2017

BRIEF-Dr.Reddy's Labs says audit of Mexican plant by USFDA completed with zero observations

* Says audit of our API Cuernavaca plant at Mexico, by US FDA, has been completed with zero observations Source text for Eikon: Further company coverage:

21 Jul 2017

Earnings vs. Estimates